EF Hutton Maintains Buy on OS Therapies, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for OS Therapies (AMEX:OSTX) and maintained a price target of $21.
October 03, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for OS Therapies and maintained a price target of $21, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $21 price target by EF Hutton suggests a positive outlook for OS Therapies. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100